Connected to India

Serving Indians Abroad


For news, views, interviews.


First human trial in Singapore for COVID-19 vaccine to begin soon: Duke-NUS

Duke-NUS Medical School and clinical-stage messenger RNA medicines company Arcturus Therapeutics will be embarking on the first human trial of a COVID-19 vaccine candidate in Singapore.

They will be initiating human dosing of LUNAR-COV19 as soon as possible. 

In a press statement, Duke-NUS Medical School said its Clinical Trial Application for the COVID-19 vaccine candidate LUNAR-COV19 has been approved to proceed by the Health Sciences Authority (HSA). 

Photo courtesy: Duke-NUS
Photo courtesy: Duke-NUS

"The healthy volunteer study will evaluate several dose levels of LUNAR-COV19 in up to 108 adults, including older adults."

Professor Ooi Eng Eong, Deputy Director of the Emerging Infectious Diseases Programme at Duke-NUS, said, “Preclinical studies on LUNAR-COV19 have shown very promising findings, including the possibility that a single dose of this vaccine may be sufficient to trigger robust and durable immune responses against SARS-CoV-2."

He added, "We are very eager to start the first-in-human clinical trial here in Singapore and advance LUNAR-COV19 on its journey to becoming a potential commercial vaccine.”

LUNAR-COV19 was developed using Arcturus’ STARR technology and a unique platform developed at Duke-NUS allowing rapid screening of vaccines for potential effectiveness and safety.

CtoI News Desk
CtoI News Desk – CtoI

Singapore-headquartered online media company targeting Indian Diaspora across Singapore, US, UK, India and UAE. Connected to India covers developments around NRIs. Cover arts, political, sports, finance, entrepreneurship, business, movies, dramas, entertainment and other news for Indians living worldwide.